Brivaracetam the 4-n-propyl analog of levetiracetam is a racetam derivative with anticonvulsant properties. Brivaracetam is believed to act by binding to the ubiquitous synaptic vesicle protein SV2. Phase II clinical trials in adult patients with refractory partial seizures were promising.
This page contains content from the copyrighted Wikipedia article "Brivaracetam"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
